Form 4: Decheng Capital Reduces BeyondSpring Stake via 10b5-1 Plan

Decheng Capital, a 10% owner and director, reported selling 11,267 ordinary shares of BeyondSpring Inc. across three transactions in mid-September 2025 under a pre-arranged trading plan.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc. (BYSI), disposed of 11,267 ordinary shares.
• The sales occurred over three separate transactions on September 17, 18, and 19, 2025.
• On September 17, 2025, 2,304 shares were sold at a weighted average price of $1.83, ranging from $1.80 to $1.88.
• On September 18, 2025, 5,307 shares were sold at a weighted average price of $1.74, ranging from $1.72 to $1.90.
• On September 19, 2025, 3,656 shares were sold at a weighted average price of $1.79, ranging from $1.72 to $1.85.
• All transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,859,333 ordinary shares.
• Other Decheng Capital entities also hold shares: Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares, and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares.
• Dr. Xiangmin Cui, manager of the general partners for these funds, is deemed to beneficially own these securities but disclaims ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be a negative signal, the execution under a 10b5-1 plan suggests these were pre-scheduled portfolio adjustments rather than a reaction to new, adverse company developments. The number of shares sold is also a small fraction of the total holdings by Decheng Capital entities.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on new, non-public information, which mitigates the negative signal typically associated with insider selling.

Negatives

• A significant shareholder and director entity, Decheng Capital, reduced its stake in BeyondSpring Inc., which could be perceived as a lack of increased conviction in the company's near-term prospects.
• The sales occurred at relatively low share prices, ranging from $1.72 to $1.90.

Risks

• Investor sentiment could be negatively impacted by the sale of shares by a major insider, potentially leading to downward pressure on the stock price.
• Despite the 10b5-1 plan, the reduction in ownership by a director and 10% owner might be interpreted by some as a signal of limited upside potential.

Related Party Transactions

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc., sold 11,267 ordinary shares to the market.
• Other Decheng Capital entities (Fund II and Global Healthcare Fund) and Dr. Xiangmin Cui are also considered related parties due to their beneficial ownership and management roles.

Stakeholder Impact

• Shareholders may view the reduction in stake by a significant insider with caution, even if pre-planned, potentially leading to questions about long-term conviction.
• The market might interpret the sales as a signal, regardless of the 10b5-1 plan, which could influence trading behavior.

Key Dates

Recommendation

The recommendation is 'hold' because while the sale by a significant insider could be a negative signal, the transactions were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not based on new, non-public information. The number of shares sold represents a relatively small portion of Decheng Capital's overall beneficial ownership in BeyondSpring Inc. Investors should monitor future filings and company performance for more definitive signals, but this specific transaction, while a reduction in stake, does not warrant an immediate 'sell' given its pre-planned nature and limited scale relative to total holdings.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Trading, Form 4, Share Sale, Beneficial Ownership, 10b5-1 Plan, Director Transaction